A 37-year-old man developed delayed non-infectious lung disease after undergoing bone marrow transplantation (BMT) for acute myeloid leukaemia. Over a 15-month period, the progression of morphologic changes from cellular interstitial pneumonia to bronchiolitis obliterans organizing pneumonia and cicatricial bronchiolitis obliterans was documented. Pulmonary function tests, high-resolution CT, bronchoalveolar lavage, lung biopsy and extensive microbiological studies were used as diagnostic tools either at onset and during the follow-up. This represents the first reported case in which a model -supported by longitudinal biopsy results -for the evolution of histologic lesions toward bronchiolitis obliterans after BMT is suggested; therapeutic implications are discussed. Bone Marrow Transplantation (2001) 28, 1167-1170. Keywords: bone marrow transplantation; bronchiolitis obliterans; bronchiolitis obliterans organizing pneumonia; delayed non-infectious lung disease; graft-versus-host disease
The term delayed non-infectious lung disease (DLD) refers to entities which occur late (Ͼ100 days) in 4 to 20% of allogeneic bone marrow transplant (BMT) recipients and for which no infectious causes can be detected. [1] [2] [3] [4] [5] We recently proposed a clinicopathologic categorization of DLD as subacute cellular interstitial pneumonia, bronchiolitis obliterans and acute lung injury. We also demonstrated these entities to be heterogeneous in regard to variables such as predominant pattern of lung involvement (airway or parenchyma), onset and clinical behaviour (acute, subacute, or chronic) and response to immunosuppressive treatment. 5, 6 The pathogenesis is still a matter of debate, although a key role for immunopathologic mechanisms related to chronic graft-versus-host disease (c-GVHD) has been strongly suggested by the identification of c-GVHD in sites other than the lung as a risk factor and by the satisfactory response to the immunosuppressive therapy observed in several previous studies. [1] [2] [3] [4] [5] However, a temporally unified view of the ongoing morphologic reactions taking place in this setting remains an enigma to us since no longitudinal biopsy results have been available until now.
We describe the progression of the histological changes in a patient with DLD after allo-BMT and correlate these findings with clinical course, high-resolution CT and bronchoalveolar lavage data.
Case report
A 37-year-old male non-smoker underwent allogeneic BMT from an unrelated volunteer donor for acute myeloid leukaemia (FAB M1 with 3;3 translocation) in July 1998, after he had received induction chemotherapy (idarubicine + Ara-C + etoposide, one cycle; Ara-C + daunorubicin, one cycle) without achieving complete remission. Conditioning consisted of total body irradiation (8 Gy in a single fraction from a linear accelerator at a dose of 7 cGy/min), antithymocyte globulin (3 mg/kg daily from day −6 to day −2), etoposide (35 mg/kg on day −2) and cyclophosphamide (60 mg/kg daily on days −3 and −2). GVHD prophylaxis included cyclosporine A and short-course methotrexate (15 mg/m 2 on days +1, then 10 mg/m 2 on days +3, +6, +11). Anti-infectious prophylaxis was acyclovir for 9 months and cotrimoxazole for 6 months. His initial course was complicated at day +41 by the occurrence of grade II acute GVHD of the skin which resolved with a short course of steroids, and at day +48 by a cytomegalovirus (CMV) infection which was successfully treated with gancyclovir and specific hyperimmunoglobulin. On day +115 the patient developed cutaneous chronic GVHD. He did well until day +390 (September 1999) when he complained of low-grade fever, dry cough and dyspnoea. Chest examination was unrevealing, as were laboratory tests including the pp65 CMV-antigenemia. Pulmonary function (PF) tests ( Figure  1 ) documented a restrictive ventilatory impairment (VC 62%, TLC 68% of predicted values) along with a severe reduction of carbon monoxide transfer (TLCO sb 44% of predicted) and a severe hypoxemia (pO 2 63 mm Hg) while breathing room air. Chest HRCT showed bilateral, patchy areas of ground glass attenuation and mild interlobular thickening ( Figure 2 ). BAL-fluid analysis (Table 1) demonstrated 700 000 cells/ml with 93% lymphocytes, 5% macro- (Figure 3a and b) . On low-dose oral steroids (prednisone 25 mg once daily), the patient experienced a complete remission of symptoms and PFT abnormalities (VC 80%, TLC 95%, and TLCO sb 74% of predicted; Figure 1 ) as well as a marked improvement of HRCT abnormalities over 2 months; steroids were tapered over the next 4 months and then stopped. One month after steroids were withdrawn (April 2000) dry cough and dyspnoea recurred, PFTs and blood gas values significantly worsened (VC 62%, TLC 68%, and TLCO sb 44% of predicted, Figure 1 ; pO 2 68 mm Hg) and HRCT revealed bilateral areas of alveolar consolidation with a peribronchial distribution, and volume loss. BAL- fluid analysis (Table 1) showed 210 000 cells/ml with 45% macrophages, 38% lymphocytes, 12% neutrophils, 5% eosinophils, and a reverse CD4/CD8 ratio (0.39); Staphylococcus aureus grew from culture. Laboratory tests revealed only an ESR at 1 h as high as 28 mm. In spite of 20-days broad-spectrum antibiotic treatment and then a 6-month course of low-dose prednisone (25 mg once daily) the patient's respiratory status progressively deteriorated.
In December 2000, he complained of dyspnoea at rest and his PFTs had dramatically worsened (VC 28% of predicted, Figure 1 ). On HRCT examination, bilateral areas of alveolar consolidation in a peribronchial distribution, bronchiectasis/bronchioloectasis and a marked volume loss were noted (Figure 4) . BAL differential count (Table 1) revealed 270 000 cells/ml with 55% macrophages, 39% neutrophils, 6% lymphocytes and a reduced CD4/CD8 ratio (0.49): extensive microbiological studies proved negative. Open lung biopsy showed a heterogeneous pattern ( Figure  5a and b) . Lymphocytic, proliferative and cicatricial bronchiolitis were distributed in a patchy fashion; areas of 'up and down' regeneration of the bronchial epithelium (alternation of cuboidal basal cells with hyperplastic tall columnar epithelium) were also present. The alveolar spaces were partially occluded by buds of granulation tissue, whereas the interstitial septa showed a patchy lymphoid infiltration. At this point, multi-drug immunosuppressive treatment (prednisone 25 mg daily, plus mofetil mycophenolate 2 g daily, plus cyclosporine A 100 mg daily) was instituted. After 4 months on therapy, the patient has improved but he still complains of exertional dyspnoea and PFTs abnormalities have not completely resolved (VC 56%, TLC 61% of predicted; Figure 1 ).
Discussion
Pathologic studies on patients with DLD after allogeneic BMT are scant and do not provide a dynamic view of the ongoing morphological changes taking place in this setting since they lack longitudinal biopsy results. In the only study in which a consistent number of lung biopsy specimens from patients with presumed pulmonary involvement by c-GVHD was systematically evaluated, Yousem 7 described four major histological categories: diffuse alveolar damage (DAD), lymphocytic bronchitis/bronchiolitis with interstitial pneumonia (BIP), bronchiolitis obliterans organizing pneumonia (BOOP), and cicatricial bronchiolitis obliterans (BO). Remarkably, he stated that BOOP findings suggested a later stage in injury than BIP, whereas BO specimens seemed to represent the late stages of BOOP and lymphocytic bronchiolitis, and could reflect irreversible pulmonary GVHD. Based on these observations, he hypothesized that an inflammatory infiltration by mononuclear cells could represent the earlier lesion, either in the airway or in the alveolar septa. The ongoing injury to interstitium and airway epithelium would cause exudation of protein and fluid into the airspaces with myofibroblast proliferation and intraluminal granulation tissue formation. Finally, the reabsorption of this granulation tissue or its progression towards fibrosis/scarring would determine the outcome.
Evolution of the histological changes in our patient seem to strengthen such a view and correlates with that of HRCT and BAL findings. At onset, transbronchial biopsy specimens only revealed a mild mononuclear infiltration of alveolar septa and damage to the alveolar epithelium leading to type-II cell hyperplasia and airspace exudation (Figure 3a and b) . HRCT showed the presence of bilateral areas of ground glass attenuation, mainly subpleural in distribution, and a mild thickening of interlobular septa (Figure 2) . BAL-fluid analysis revealed a huge increase in lymphocyte percentage, which has been recognized as the main feature of cellular interstitial pneumonia after allogeneic BMT. 5, 8 The open lung biopsy specimens, which testify to the evolution of lesions, showed the contemporaneous presence of the three histologic stages proposed by Yousem ( Figure  5a and b) . A marked inflammatory infiltration, predominantly lymphocytic in nature, was present either in the alveolar septa and, especially, in the bronchiolar walls. The airspaces were filled with polyps of granulation tissue. Some bronchioles had subepithelial foci of fibroblastic proliferation causing narrowing of their lumen, which could account for an initial tendency of the process towards fibrosis/scarring. In fact, cicatritial bronchiolitis with airways dilatation was also present. On HRCT examination, bilateral diffuse areas of alveolar consolidation with a peribronchial distribution reflected the BOOP histological pattern and were the likely cause of the relevant volume loss; bronchiectasis and bronchioloectasis were probably correlated with the evolution toward cicatricial bronchiolitis (Figure 4) . The modifications of BAL profile from onset to open lung biopsy (Table 1) were characterized by a progressive reduction in lymphocytes and an increase in neutrophil percentage, the latter becoming typically high in patients with cicatricial bronchiolitis. 5, 9 A possible criticism of our paper is that the spectrum of histological lesions observed at the time of OLB was already present at the onset of the respiratory illness but was not completely disclosed by tiny TBB specimens, due to sampling error. Although we considered such an eventuality, we tend to rule it out since HRCT findings, BAL profile, and response to immunosuppressive treatment observed at onset and at the time of OLB depict two very different clinicopathologic entities.
In conclusion, our case study suggests for the first time a model of evolution of the histological lesions supported by longitudinal biopsy results in the setting of DLD after allo-BMT. This model seems to strengthen the hypothesis by Yousem considering BO as the end-stage damage of the pulmonary GVHD, although further studies are needed to confirm this view. In clinical practice, we believe that early and protracted immunosuppressive treatment, along with careful follow-up should be provided for cases of cellular interstitial pneumonia and BOOP, which seem still to represent potentially reversible lesions.
